Resistance to the main drug in front-line malaria treatments is becoming more widespread across East Africa, according to new research by Imperial College London. The study, published in The Lancet Infectious Diseases, maps the rise in artemisinin resistance in the region and suggests one of the safeguards built into these treatments is being eroded. The researchers warn that their findings…
Source: Medical Xpress
